Learning from failure: congestive heart failure in the postgenomic age.
The prognosis of heart failure is worse than that of most cancers, but new therapeutic interventions using stem and other cell-based therapies are succeeding in the fight against it, and old drugs, with new twists, are making a comeback. Genetically engineered animal models are driving insights into the molecular mechanisms that cause hearts to fail, accelerating drug discoveries, and inspiring cell-based therapeutic interventions for both acquired and inheritable cardiac diseases.
Benjamin
Ivor J
IJ
Division of Cardiology, Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA. ivor.benjamin@hsc.utah.edu
Schneider
Michael D
MD
D000818:Animals; D030801:Animals, Genetically Modified; D017209:Apoptosis / Q000502:physiology; D002118:Calcium / Q000378:metabolism; D015316:Genetic Therapy; D023281:Genomics; D006333:Heart Failure / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress; D011494:Protein Kinases / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D014158:Transcription, Genetic
D009569:Nitric Oxide; D011494:Protein Kinases; D002118:Calcium